[{"id":"prime-pp-nrs","name":"Pruritus improvement (WI-NRS ≥4 point reduction) at Week 24","type":"PRIMARY","unit":"%","results":[{"notes":"60% vs 18% placebo","value":60,"arm_id":"dupixent-pn-prime","p_value":"<0.001","arm_name":"Dupilumab"},{"value":18,"arm_id":"placebo-pn-prime","arm_name":"Placebo"}],"timepoint":"Week 24","description":"Proportion achieving clinically meaningful itch reduction (≥4-point on Worst Itch NRS 0-10). PN causes severe, debilitating itch."}]

PRIME: 60% itch reduction vs 18% placebo (p<0.001). IGA 0/1: 48% vs 18%. First FDA-approved treatment for PN.

PRIME (n=151): Excellent tolerability. Nasopharyngitis 8% vs 9%.

PRIME: 60% vs 18% itch reduction is dramatic for patients with no prior options. PN itch is among the worst in dermatology.

PN: severe intractable itch with hard nodules. No FDA-approved therapy existed.